Official websites use. Share sensitive information only on official, secure websites. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.
If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. There are currently no approved pharmacological treatments to improve social reciprocity and limit repetitive and rigid behaviors in autism spectrum disorder ASD. The primary endpoint of each is change in Childhood Autism Rating Scale 2 total raw score after 6 months.
These studies could contribute to the first pharmacological treatment to improve social reciprocity and limit repetitive and rigid behaviors in children and adolescents with ASD. Keywords: Autism spectrum disorder, Bumetanide, Pediatrics, Randomized controlled trial. Autism spectrum disorder ASD is a lifelong neurodevelopmental condition characterized by an early onset of persistent deficits in communication and social interaction across multiple contexts, and the presence of restrictive, repetitive patterns of behaviors, interests, or activities American Psychiatric Association , Today, no pharmacological treatments exist for these symptoms.
Associated symptoms and behaviors such as irritability, self-injuriousness, temper tantrums, quickly changing moods, sleep disturbances, anxiety, or depressive disorders are frequently reported Fitzpatrick et al.
ASD is more common in males than females, with a gender ratio of approximately in community studies Loomes et al. The gender difference may be caused by under- or mis-diagnosis in females Loomes et al. The global prevalence of ASD in children is estimated to be 7.
